Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Key FDA reform bills could be undermined by pre-emption clause

This article was originally published in Clinica

Executive Summary

US House Democrats drafted a package of Food and Drug Administration reform bills late last week that included a few tiny lines that caused a big fuss at a hearing on Tuesday June 12. Those lines would prohibit FDA law from pre-empting state court damage claims that opponents say could potentially jeopardise passage, writes April Fulton.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048858

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel